AJU-A53

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameAJU-A53

Drug Alias NameDapagliflozin/Linagliptin/Metformin HydrochlorideAJU-A53

ClassificationSmall molecules

Mechanisms of ActionSodium/glucose cotransporter 2 inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors

TargetsSodium/glucose cotransporter 2Protein kinase AMP-activated non-catalytic subunit beta 1Dipeptidyl peptidase IV

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsYes

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAju Pharm Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesAju Pharm Co Ltd

Inactive CompaniesN/A

Active IndicationsDiabetes Mellitus, Type 2

Inactive IndicationsN/A

Other Information

ATC CodeN/A